[1] BONETTI F, PEA M, MARTIGNONI G, et al. PEC and sugar[J]. Am J Surg Pathol, 1992, 16(3): 307-308.
[2] ZHANG C, PAN F, QIAO J, et al. Perivascular epithelioid cell tumor of the cervix with malignant potential[J]. Int J Gynaecol Obstet, 2013, 123(1): 72-73.
[3] 罗家寿, 罗雪珍, 黄雯, 等. 子宫血管周上皮样细胞肿瘤2 例[J]. 实用妇产科杂志, 2013, 29(7): 558-559.
[4] THWAY K, FISHER C. PEComa: morphology and genetics of a complex tumor family[J]. Ann Diagn Pathol, 2015, 19(5): 359-368.
[5] FADARE O. Perivascular epithelioid cell tumor (PEComa) of the uterus: an outcome-based clinicopathologic analysis of 41 reported cases[J]. Adv Anat Pathol, 2008, 15(2): 63-75.
[6] SCHOOLMEESTER J K, HOWITT B E, HIRSCH M S, et al. Perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: Clinicopathologic and immunohistochemical characterization of 16 cases[J]. Am J Surg Pathol, 2014, 38(2): 176-188.
[7] FOLPE A L, MENTZEL T, LEHR H A, et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature[J]. Am J Surg Pathol, 2005, 29(12): 1558-1575.
[8] WAGNER A J, MALINOWSKA-KOLODZIEJ I, MORGAN J A, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors [J]. J Clin Oncol, 2010, 28(5): 835-840.
[9] ITALIANO A, DELCAMBRE C, HOSTEIN I, et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa[J]. Ann Oncol, 2010, 21(5): 1135-1137.
